News from CROI 2015

The annual Conference on Retroviruses and Opportunistic Infections (CROI 2015) is taking place in Seattle, USA, in late February.

Our writers will be reporting on key research presented at the conference, publishing news and sending out CROI news summary bulletins by email, three during the conference week and one the following week.

“The coverage made me feel I was at the conference and I appreciate NAM's effort in sharing the bulletins.” NAM bulletin subscriber

aidsmap news from CROI 2015

HIV attachment inhibitor BMS-663068 safe and effective in phase 2b study

Bristol-Myers Squibb's BMS-663068 or fostemsavir, a first-in-class HIV attachment inhibitor that stops the virus from binding to and entering cells, was well-tolerated and demonstrated good antiviral activity in

Published
04 March 2015
By
Liz Highleyman
Deferring hepatitis C treatment can lead to liver cancer and death, despite cure

People with HIV and hepatitis C co-infection who delay hepatitis C treatment remain at risk for liver failure, hepatocellular carcinoma and liver-related death even after being

Published
03 March 2015
By
Liz Highleyman
Progression to severe fibrosis or cirrhosis is common among baby boomers with hepatitis C in the US

The burden of hepatitis C virus (HCV) infection is high in the US, with a substantial number of individuals born between 1945 and 1965 having advanced liver

Published
03 March 2015
By
Liz Highleyman
Study finds high rates of cancer among older people living with HIV

Older people living with HIV (over the age of 65) are at greatly increased risk of HIV-associated cancers, although many of the most commonly diagnosed cancers may

Published
03 March 2015
By
Theo Smart
Levels of maraviroc in vaginal and rectal tissues may not be high enough for pre-exposure prophylaxis

Levels of the HIV entry inhibitor maraviroc (Celsentri/Selzentry) in vaginal and rectal tissues did not reach high enough levels with a single oral dose to confer protection

Published
02 March 2015
By
Liz Highleyman
Financial incentives did not improve linkage to care or viral suppression in US study

A US study which offered patients gift cards to present themselves for HIV care after testing, and also to stay in care and maintain an undetectable viral

Published
28 February 2015
By
Gus Cairns
Tenofovir, boosted atazanavir and boosted lopinavir are associated with cumulative risk of developing chronic kidney disease

Three antiretroviral drugs are associated with a slowly increasing rate of chronic kidney disease over time, the Conference on Retroviruses and Opportunistic Infections (CROI 2015) in

Published
27 February 2015
By
Gus Cairns
Two interferon-free regimens show high HCV cure rates for people with HIV and HCV co-infection

A pair of two-drug, 12-week regimens containing neither interferon nor ribavirin – sofosbuvir (Sovaldi) plus either ledipasvir (the Harvoni coformulation) or daclatasvir (Daklinza) – cured hepatitis

Published
27 February 2015
By
Liz Highleyman
Tenofovir alafenamide equally effective but safer for kidneys and bones than current formulation

Tenofovir alafenamide (TAF), a new formulation that has lower concentrations in the blood but reaches higher levels in cells, is as effective as the older version, tenofovir disoproxil

Published
27 February 2015
By
Liz Highleyman
Treatment cascades and viral load surveys show how African countries can maximise prevention benefits of HIV treatment

Reaching ambitious HIV prevention targets in South Africa will require intensified efforts to engage and retain men and young people in care, in order to increase the

Published
27 February 2015
By
Keith Alcorn
← Prev12345Next →

Email bulletins

Sign up for our conference bulletins

Find out more and sign up to the full range of aidsmap email bulletins >

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.